Point72 Hong Kong LTD Aeglea Bio Therapeutics, Inc. Transaction History

Point72 Hong Kong LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $1,960 - $10,429	-3,921 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $7,046 - $17,973	3,768 Added 2462.75%	3,921 $9,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $535 - $1,288	153 New	153 $1,000
Q1 2021 May 17, 2021	SELL	$6.76 - $8.57 $175 - $222	-26 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$7.02 - $9.83 $8,929 - $12,503	-1,272 Reduced 98.0%	26 $0
Q3 2020 Nov 16, 2020	BUY	$6.51 - $9.33 $8,449 - $12,110	1,298 New	1,298 $9,000
Q4 2018 Feb 14, 2019	SELL	$6.51 - $10.19 $9,895 - $15,488	-1,520 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.24 - $11.0 $8,116 - $10,835	985 Added 184.11%	1,520 $15,000
Q2 2018 Aug 14, 2018	BUY	$7.87 - $10.89 $4,210 - $5,826	535 New	535 $6,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.